Commercialization of catalytic enhancers targeting IDO1 for multiple sclerosis

Project description

A novel drug against multiple sclerosis

Multiple sclerosis (MS) is a chronic neurodegenerative disease characterised by debilitating relapses associated with loss of neurological function. MS affects millions of individuals worldwide, but existing treatment options are primarily palliative. The EU-funded ENHANCIDO project aims to evaluate novel small molecules potentiating the activity of the immunosuppressive enzyme IDO1 known to reduce MS severity in animal models. By evaluating the efficacy, pharmacokinetics and pharmacodynamics of these compounds, scientists hope to deliver an innovative first-in-class drug that will improve the lives of MS patients. More importantly, this drug has the potential to be used to treat other autoimmune diseases.

Fields of science

Host institution

UNIVERSITA DEGLI STUDI DI PERUGIA

Net EU contribution

€ 150 000,00

Address

Piazza Dell Universita 1
06123 Perugia
Italy

Region

Centro (IT) Umbria Perugia

Activity type

Higher or Secondary Education Establishments

Links

Contact the organisation Website

Participation in EU R&I programmes

HORIZON collaboration network

Other funding

No data

Beneficiaries (1)